Speaker List - 4th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference UK/EU

4th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference UK/EU

6th - 7th October 2022 | ISH Venues, 1 Park Cres, London W1B 1SH, United Kingdom
CONFERENCE SPEAKERS
Speakers
Katerina-Vanessa Savva
Katerina-Vanessa Savva
Researcher,
Imperial College London


Katerina-Vanessa Savva is a PhD candidate at Imperial College London, department of Surgery and Cancer. Upon completion of her BSc in Biomedical Sciences from the University of Sheffield (2017), she perused an MRes in Biomedical Research at Imperial College London (2018) where she was exposed to analytical chemistry and clinical research. Her PhD research project focuses on the development of the Biomarker Toolkit. A tool that has the potential to act as a framework which funders, researchers, academics, clinicians, industry personnel can equally use in a consistent manner to: i) improve research quality, ii) standardise biomarker research while iii) assessing which biomarkers have higher potential and should therefore get funded for research. 


Heino Heyman
Heino Heyman
Metabolomics Application Specialist,
Metabolon



Alain Wagner
Alain Wagner
Co-founder,
MicroOmiX Tech


Alain Wagner is Director of Research at the CNRS and heads the BioFunctional Chemistry team of the UMR 7199 at the Faculty of Pharmacy in Strasbourg. He is interested in manipulating living systems through the use, in situ, of chemical reactions capable of operating in complex biological media. His work particularly focusses on development of cleavable linkers and payloads with new or combined mode of action for safer Antibody Drug Conjugate (ADC). Alain also pioneer a microfluidic technology allowing for the analysis and sorting of large population of single cells on the basis of their secretory activity. In 2021 Alain co-founded MicroOmiX s start-up developing advanced single cell-based R&D in the field of antibody and cell-based product development. Combining research and technology transfer Alain is author of more than 160 peer reviewed publications, inventor of 30 patents and co-founder of 5 start-ups.


Bart Westendorp
Bart Westendorp
Assistant Professor, Department of Biomolecular Health Sciences,
Utrecht University, The Netherlands


Bart Westendorp is a cell biologist and group leader at Utrecht University. He studies DNA replication stress and cell cycle checkpoint signalling in cancer cells using single cell technology. Single cell analysis has revealed great intra-tumor heterogeneity. Subsets of cells can modify their cell division machinery such that they can tolerate the drug treatment. These so-called drug-tolerant persister cells are able to survive and even proliferate despite presence of DNA damaging drugs, such as chemotherapy and targeted cell cycle checkpoint inhibitors. Bart Westendorp and his team study the dynamic cell proliferation behaviour of individual cancer cells and emergence of drug resistance in muscle-invasive bladder cancer using single cell RNA-sequencing, live cell imaging, and flow cytometry.


Jelmar Quist
Jelmar Quist
Cancer Bioinformatician,
King’s College London


Jelmar Quist obtained a PhD studentship in Translational Medicine from the NIHR Biomedical Research Centre at Guy’s and St Thomas’. After finishing his PhD in Cancer Bioinformatics, he worked on understanding how cancer testis antigens influence the tumour immune microenvironment and the DNA damage response in triple-negative breast cancers with the aim of improving patient stratification. He is currently working on predicting response to neoadjuvant chemotherapy through spatial transcriptomics.


Brid Ryan
Brid Ryan
Vice President,
MiNA Therapeutics


Bríd is Vice President of Oncology and Immunology Research at MiNA Therapeutics, leading research and pre-clinical programs. She previously spent 14 years at the National Cancer Institute in the US, where she was a Principal Investigator for eight years working on precision medicine and biomarkers in lung cancer. Bríd has a BSc Honours in Biochemistry from University College Cork, a PhD in Cancer Biology from University College Dublin, and a Masters of Public Health from University College Dublin. Prior to being a Principal Investigator, she completed a prestigious postdoctoral fellowship at The National Cancer Institute and is the author of more than 70 peer-reviewed publications. Bríd joined MiNA in May of 2021.


Sreejith Raveendran
Sreejith Raveendran
Assistant Professor,
Teesside University


Dr. Sreejith Raveendran is currently working as Lecturer/ Assistant Prof. in Biotechnology at School of Health and Life Sciences and Research Group Leader at National Horizon Centre, Teesside University, North-East England. He pursued his Ph.D. in Bionanoscience with an emphasis on cancer drug delivery and nanomedicine from Toyo University, Japan in 2013. Since then, he is pursuing his research in Cancer nanotechnology and targeted combination nanotherapeutics. Sree focuses on the novel combinatorial approaches in immunochemo therapies of cancer and infectious diseases via bionanotechnological platforms. He synthesizes & characterizes novel nanoparticle formulations with multiple functional moieties, chemotherapeutic agents and imaging modalities that specifically binds to the target proteins in cancer cells. He studies the cellular and molecular mechanisms behind the nanoparticle toxicity, drug activity and immunological stimulations after specific targeting through new multimodal therapeutics. He worked as Project Coordinator for India -Japan Bionano Mission Project at Indian Institute of Technology -Delhi (2019-2022), Marie Sklodowska Curie ActionIndividual fellow at University of Brighton (2017-2019), Postdoctoral Research fellow, BNERC, Toyo University, Japan (2013-2017), Research Associate in Infection pharmacology at AstraZeneca India (2009-2010), and Junior Research Associate in Abl Biotechnologies Ltd., India (2008-2009), during his career. Sree’s progress has remarked well with several high- impact publications, book chapters, invited talks and conference presentations and he has been recognized on several occasions with prestigious awards and honours.


Patrick Brossard
Patrick Brossard
Principal Clinical Pharmacologist,
SOBI


Patrick Brossard, PhD, joined SOBI (Swedish Orphan Biovitrum) in 2021 as principal clinical pharmacologist, managing and responsible for all clinical pharmacology related activities within the company. Prior to that, he worked for over 18 years in the field of clinical pharmacology, managing clinical pharmacology activities and working closely with other functions to bring compounds from early development to phase III, across various indications such as immunology, neurology or cardiovascular, with various types of drugs (including small molecules and biologics) via different routes of administration (iv, oral, inhalation or topical). During his career, he made extensive use of biomarkers to guide dosing regimen selection and regimen from entry in human up to phase III trials.


Hemmel Amrania
Hemmel Amrania
Research Scientist,
Imperial College London


Hemmel is a Clinical Scientist from Charing Cross Hospital - Imperial College London - where he leads clinical trials under Prof Charles Coombes and Prof Sir Nicholas Wright the decorated pathologist and Head of Pathology at Cancer Research UK. He patented a novel method to grade tumour biopsies that eliminated non-concordance due to subjective bias and was awarded the President’s Award for Outstanding Research at Imperial College. Later he was recipient of the Royal Society Innovation Prize and also the Cancer Research Pioneer Award. After learning of the challenges breast oncologists face in determining patient risk (>90% of breast cancer patients cannot afford the diagnostics recommended to mitigate chemotherapy use) he sought to apply his research to solve this problem. He developed Digistain - a radically faster and cost effective way to select patients who could safely avoid chemotherapy saving the health payer significant costs whilst improving patient outcome. Prominent backers for his research include Y Combinator and Harvard University, CRUK and National Institute of Health Research


Jennifer Barnett
Jennifer Barnett
CEO,
Monument Therapeutics


Jenny has an MA in Experimental Psychology from Oxford University, a PhD in the epidemiology of schizophrenia from the University of Cambridge and completed post-doctoral work at Massachusetts General Hospital and the Broad Institute of Harvard and MIT. She joined Cambridge Cognition in 2008 and worked i Jenny has an MA in Experimental Psychology from Oxford University, a PhD in the epidemiology of schizophrenia from the University of Cambridge and completed post-doctoral work at Massachusetts General Hospital and the Broad Institute of Harvard and MIT. She joined Cambridge Cognition in 2008 and worked in the clinical trial, healthcare, and R&D functions before joining the senior management team in 2014 and becoming CSO in 2016.

She has worked on the design and analysis of more than 100 cognitive trials and is the author of 60+ scientific publications and six patents. She has led IP strategy, KOL networking and the scientific validation of medical devices for regulatory approvaln the clinical trial, healthcare, and R&D functions before joining the senior management team in 2014 and becoming CSO in 2016. She has worked on the design and analysis of more than 100 cognitive trials and is the author of 60+ scientific publications and six patents. She has led IP strategy, KOL networking and the scientific validation of medical devices for regulatory approval.


Samaneh Kouchaki
Samaneh Kouchaki
Lecturer, Machine Learning,
University of Surrey


Samaneh Kouchaki is Lecturer in Machine learning for Healthcare at the Department of Electronic and Electrical Engineering and a member of the Centre for Vision, Speech and Signal Processing (CVSSP) at the University of Surrey and the UK Dementia Research Institute at Imperial Collage London. Her research interests include machine learning, health informatics, biomedical signal processing and computational biology.


Yong-Jie Lu
Yong-Jie Lu
Professor of Molecular Oncology (Barts Cancer Institute),
Queen Mary University of London (QMUL)


Professor Yong-Jie Lu is a professor in Molecular Oncology at Barts Cancer Institute, Queen Mary University of London. His past work has been mainly focused on identification of genetic alterations and genetic mechanisms in cancer development, progression and therapeutic response. Recently, his research work moved into circulating biomarker development, aiming to translate them into cancer diagnosis, prognosis and therapeutic stratification. He published more than 100 peer reviewed original studies, in journals including Lancet, PNAS, Nature Genetics, Journal Clinical Oncology, Cancer Research and Clinical Cancer Research. He also published several review articles and book chapters. His finding in circulating tumour and other cell biomarkers have been reported as research news in multiple national and international media, including TV, radio, newspaper and online news media. He has filled two patent applications for prostate cancer prognosis using circulating cell biomarkers. He has been serving as editorial board members for a number of international scientific journals.


James Miles
James Miles
Product Manager,
HAWK Biosystems


James recently obtained his PhD in 2022, titled: The Role of Interactive States of Immune Checkpoint Regulators in Cancer: Determined by Quantitative Imaging, in a cotutelle between the University of the Basque Country, the University of Bordeaux and HAWK Biosystems. Since 2021, James has been the Product Manager at HAWK Biosystems. During his undergraduate degree in Pharmacology, at the University of Bath, James spent a year working in the Cell Biophysics Laboratory headed by Prof. Banafshe Larijani. Within this placement, James utilised a novel FRET/FLIM imaging assay to assess the activation state of Akt/PKB and STAT3 in clear-cell renal cell carcinoma (ccRCC). During his PhD, James applied this FRET/FLIM assay, now known as QF-Pro® to determine the interaction states of PD-1/PD-L1 and CTLA-4/CD80 to a range of solid tumours, including RFA-treated lung metastases. James has extensive knowledge and experience working with the QF-Pro® assay and has been well placed to help begin transitioning QF-Pro® from an assay-service to a commercial product.


Batika Rana
Batika Rana
Senior Scientist,
Orchard Therapeutics


Batika Rana is a Senior Scientist currently leading the early analytical development team for autologous stem cell therapy at Orchard Therapeutics. The team focuses on novel potency assay, characterisation and residual assay implementation and qualification to support process development, R&D and an external CDMO. Batika gained a BSc and MSc in Immunology from the University of Glasgow and KCL respectively and performed her post-doctoral studies at the Laboratory of Molecular Biology in Cambridge.  Her previous experience involves the characterisation of cellular interactions, gene expression by single cell sequencing and the use of lentiviral and CRISPR based systems to assess gene function in primary human cells and in vivo models. She initially joined Orchard Therapeutics’ R&D team in early 2019 to implement cell phenotyping workflows and transitioned to CGT in 2021 where she was integral to establishing the internal analytical development team.


Nagy Habib
Nagy Habib
Founder and Head of R&D,
MiNA Therapeutics


Nagy is a founder and Head of R&D of MiNA Therapeutics. For over three decades Nagy has been at the forefront of clinical research and clinical practice in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. Currently, he is driving the development of an saRNA drug (a new class of medicines) which is currently being trialed in patients with liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, ClinicalTrials.gov ID NCT02716012), a second trial in patients with solid tumours (TIMEPOINT study, ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan and OUTREACH2 study, which is a randomised phase II follow-on study in patient with viral HCC (ClinicalTrials.gov ID NCT 04710641). He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Previously Nagy was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018). Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London


Andrew Pierce
Andrew Pierce
Vice President, Translational Biology,
Crescendo Biologics


Andrew has been leading translational biology teams for nearly 20 years with international industrial experience developing both small and large molecule oncology drugs. He began his career on the faculty of the University of Kentucky before joining N of One Therapeutics, MedImmune (USA) and subsequently AstraZeneca (UK). Andrew has brought multiple therapeutic candidates into and through clinical development including immunotherapies, antibody/drug conjugates, DNA damage/repair modulators and classical cell signalling inhibitors.

Andrew has a BSci degree from the University of Toronto in Canada, and a PhD in molecular genetics from the University of North Carolina at Chapel Hill. He has published over 40 papers in peer-reviewed journals and serves on the Molecular and Cellular Medicine Board of the MRC (UK).


Ian Pike
Ian Pike
Chief Scientific Officer,
Proteome Sciences PLC


Ian Pike is the Chief Scientific Officer at Proteome Sciences and has over 30 years’ experience working in the diagnostics and biotechnology sectors. Since joining Proteome Sciences in 2002 he has held a number of roles covering intellectual property management, business development, operational management and is now focused on leading the Company’s scientific strategy to offer clients a flexible, high-quality service.